- Home
- TIGR vs SANA Comparison
TIGR vs SANA Comparison
Compare TIGR & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TIGR | SANA |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TIGR | SANA |
|---|---|---|
| Price | $7.18 | $3.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $14.20 | $7.50 |
| AVG Volume (30 Days) | 1.8M | ★ 1.9M |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.24 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $79.26 | N/A |
| Revenue Next Year | $5.17 | N/A |
| P/E Ratio | $9.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.38 | $1.27 |
| 52 Week High | $13.55 | $6.55 |
Technical Indicators
Market Signals| Indicator | TIGR | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 32.14 | 29.96 |
| Support Level | N/A | $3.16 |
| Resistance Level | $8.77 | $3.24 |
| Average True Range (ATR) | 0.27 | 0.26 |
| MACD | -0.04 | -0.09 |
| Stochastic Oscillator | 9.87 | 7.61 |
Price Performance
Historical ComparisonAbout TIGR UP Fintech Holding Ltd representing fifteen
UP Fintech Holding Ltd is an online brokerage firm focusing on Chinese investors. Its trading platform enables investors to trade in equities and other financial instruments on multiple exchanges of stocks and other derivatives. The company offers its customers brokerage and value-added services, including trade order placement and execution, margin financing, account management, investor education, community discussion, and customer support.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.